Efficacy Study of Digibind for Treatment of Severe Preeclampsia
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a commercially available anti-digoxin
antibody, Digibind, can delay delivery in patients with severe pre-eclampsia. If so, this
would allow more time for maternally administered steroids to prevent the development of
respiratory complications in premature infants.
Phase:
Phase 2
Details
Lead Sponsor:
BTG International Inc.
Collaborator:
GlaxoSmithKline
Treatments:
Antibodies Digoxin Immunoglobulin Fab Fragments Immunoglobulins